Literature DB >> 6665534

[Amodiaquine-induced agranulocytosis in malaria prevention: demonstration of an amodiaquine-induced cytotoxic antibody against granulocytes].

H K Schulthess, A von Felten, J Gmür, K Neftel.   

Abstract

A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria. An amodiaquine-dependent granulocytotoxic antibody could be demonstrated in the patient's serum on day 1 after stopping amodiaquine medication. Granulocyte transfusion was ineffective on days 6 and 7, possibly due to the slow elimination of the drug.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6665534

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN： 0036-7672


  4 in total

1.  Discovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by Organophosphates.

Authors:  Francine S Katz; Stevan Pecic; Timothy H Tran; Ilya Trakht; Laura Schneider; Zhengxiang Zhu; Long Ton-That; Michal Luzac; Viktor Zlatanic; Shivani Damera; Joanne Macdonald; Donald W Landry; Liang Tong; Milan N Stojanovic
Journal:  Chembiochem       Date:  2015-09-09       Impact factor: 3.164

2.  Amodiaquine induced agranulocytosis and liver damage.

Authors:  K A Neftel; W Woodtly; M Schmid; P G Frick; J Fehr
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

3.  Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial.

Authors:  Djibrine Djallé; Siméon P Njuimo; Alexandre Manirakiza; Rémi Laganier; Alain Le Faou; Christophe Rogier
Journal:  Malar J       Date:  2014-01-07       Impact factor: 2.979

4.  Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4.

Authors:  Shaowei Wang; Boyang Li; Victoria Solomon; Alfred Fonteh; Stanley I Rapoport; David A Bennett; Zoe Arvanitakis; Helena C Chui; Carol Miller; Patrick M Sullivan; Hoau-Yan Wang; Hussein N Yassine
Journal:  Mol Neurodegener       Date:  2021-04-16       Impact factor: 14.195
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.